India Premier Pushes For Generic Prescriptions But Hurdles Loom
India’s prime minister has declared that doctors should prescribe medicines using only non-proprietary generic names in an effort to reduce medical bills, but the medical fraternity says the move could jeopardize patient safety, while hurdles mean others see only limited pharma industry impact in the short term.
You may also be interested in...
IQVIA’s general manager (South Asia), Amit Mookim, outlines the reasons for scaling down the five-year outlook for the Indian pharmaceutical market, including a near halving of the prognosis for 2017.
2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.
Japan’s Santen appears set for a scale up in India via an alliance with Centaur Pharmaceuticals. The partners outline to Scrip the broad contours of the India plan.